INVITRO LIVER CANCER POTENTIAL OF ETHANOLIC EXTRACT OF TRIBULUS LANUGINOSUS

The current investigation was conducted to assess the ethanolic extract of Tribulus lanuginosus in vitro anticancer potential against liver cancer cell lines. A significant worldwide health issue linked to oxidative stress, persistent inflammation, and increasing liver damage is liver cancer, especially hepatocellular carcinoma. The hepatoprotective and anticancer potential of medicinal plants that include bioactive phytochemicals including flavonoids, saponins, and phenolic compounds is being studied more and more. Tribulus lanuginosus leaves were gathered, verified, shade-dried, and extracted with ethanol in this study. Initial phytochemical screening verified the existence of significant secondary metabolites. After that, the extract's cytotoxic activity was assessed on liver cancer cell lines using conventional in-vitro techniques. Significant anticancer potential was shown by the results, which showed a dose-dependent inhibitory effect on cancer cell survival that may be connected to cytoprotective and antioxidant pathways. Overall, the study supports Tribulus lanuginosus potential use as a natural source of hepatoprotective and anticancer drugs; nevertheless, more research is advised to identify active chemicals and verify efficacy through sophisticated experimental and clinical studies.

• El-Serag, H.B. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142(6): 1264–1273.
• Bray, F., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates. CA: A Cancer Journal for Clinicians, 68(6): 394–424.
• Forner, A., Reig, M., & Bruix, J. (2018). Hepatocellular carcinoma. The Lancet, 391:         1301–1314.
• Llovet, J.M., et al. (2016). Hepatocellular carcinoma. Nature Reviews Disease Primers, 2: 16018.
• Bosch, F.X., Ribes, J., Díaz, M., & Cléries, R. (2004). Primary liver cancer worldwide. Gastroenterology, 127: S5–S16.
• Farazi, P.A., & DePinho, R.A. (2006). Hepatocellular carcinoma pathogenesis. Nature Reviews Cancer, 6: 674–687.
• Aravalli, R.N., Steer, C.J., & Cressman, E.N.K. (2008). Molecular mechanisms of hepatocellular carcinoma. Hepatology, 48(6): 2047–2063.
• Wallace, M.C., et al. (2015). Liver fibrosis and cancer development. Journal of Hepatology, 63(1): 237–264.
• Cragg, G.M., & Newman, D.J. (2013). Natural products in cancer therapy. Biochimica et Biophysica Acta, 1830: 3670–3695.
• Greenwell, M., & Rahman, P.K.S.M. (2015). Medicinal plants: Their use in anticancer treatment. International Journal of Pharmaceutical Sciences, 6(10): 4103–4112.
• Newman, D.J., & Cragg, G.M. (2020). Natural products as sources of drugs. Journal of Natural Products, 83(3): 770–803.
• Chhatre, S., Nesari, T., Somani, G., Kanchan, D., & Sathaye, S. (2014). Phytopharmacological overview of Tribulus lanuginosus. Pharmacognosy Reviews, 8(15): 45–51.
• Kostova, I., & Dinchev, D. (2005). Saponins in Tribulus species. Phytochemistry Reviews, 4:       111–137.
• Singh, S., Nair, V., & Gupta, Y.K. (2012). Tribulus lanuginosus and related species: Pharmacology. Journal of Ethnopharmacology, 139: 1–10.
• Evans, W.C. (2009). Trease and Evans Pharmacognosy (16th ed.). Saunders Elsevier.
• Harborne, J.B. (1998). Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis (3rd ed.). Chapman & Hall.
• Khandelwal, K.R. (2008). Practical Pharmacognosy: Techniques and Experiments (19th ed.). Nirali Prakashan.
• Kokate, C.K., Purohit, A.P., & Gokhale, S.B. (2010). Pharmacognosy (45th ed.). Nirali Prakashan.
• Rice-Evans, C.A., Miller, N.J., & Paganga, G. (1997). Antioxidant properties of phenolic compounds. Trends in Plant Science, 2: 152–159.
• Middleton, E., Kandaswami, C., & Theoharides, T.C. (2000). Flavonoids and biological effects. Pharmacological Reviews, 52: 673–751.
• Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival (MTT assay). Journal of Immunological Methods, 65: 55–63.
• Freshney, R.I. (2016). Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications (7th ed.). Wiley-Blackwell.
• Denizot, F., & Lang, R. (1986). Rapid colorimetric assay for cell growth. Journal of Immunological Methods, 89: 271–277.
• Llovet, J.M., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359: 378–390.
• Kudo, M., et al. (2018). Lenvatinib versus sorafenib in liver cancer. The Lancet, 391: 1163–1173.
• Sebaugh, J.L. (2011). Guidelines for accurate EC50/IC50 estimation. Pharmaceutical Statistics, 10(2): 128–134.
• Fotakis, G., & Timbrell, J.A. (2006). In-vitro cytotoxicity assays comparison. Toxicology Letters, 160: 171–177.